Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-Β
journal contribution
posted on 2023-05-21, 15:00 authored by Steve Simpson JRSteve Simpson JR, Pirmani, A, De Brouwer, E, Peeters, LM, Geys, L, Parciak, T, Helme, A, Hillert, J, Moreau, Y, Edan, G, Spelman, T, Sharmin, S, McBurney, R, Schmidt, H, Bergmann, A, Braune, S, Stahmann, A, Middleton, R, Salter, A, Bebo, B, van der Walt, A, Butzkueven, H, Ozakbas, S, Karabudak, R, Boz, C, Alroughani, R, Rojas, JI, Ingrid van der MeiIngrid van der Mei, Sciascia do Olival, G, Magyari, M, Alonso, R, Nicholas, R, Chertcoff, A, Zabalza, A, Arrambide, G, Nag, N, Descamps, A, Costers, L, Dobson, R, Miller, A, Rodrigues, P, Prckovska, V, Comi, G, Kalincik, TBackground: Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS.
Results: Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs.
Conclusions: In comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-β. This study does not support the use of interferon-β as a treatment to reduce COVID-19 severity in MS.
History
Publication title
Multiple Sclerosis and Related DisordersVolume
66Article number
104072Number
104072Pagination
1-5ISSN
2211-0348Department/School
Menzies Institute for Medical ResearchPublisher
Elsevier B. V.Place of publication
NetherlandsRights statement
© 2022 Elsevier B.V.Repository Status
- Restricted
